Raymond James & Associates increased its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 11.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 37,227 shares of the company’s stock after purchasing an additional 3,972 shares during the quarter. Raymond James & Associates’ holdings in CRISPR Therapeutics were worth $2,433,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. raised its stake in CRISPR Therapeutics by 26.5% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 26,280 shares of the company’s stock worth $1,717,000 after buying an additional 5,498 shares during the last quarter. Eqis Capital Management Inc. boosted its stake in shares of CRISPR Therapeutics by 106.6% in the 3rd quarter. Eqis Capital Management Inc. now owns 26,437 shares of the company’s stock valued at $1,728,000 after purchasing an additional 13,638 shares in the last quarter. Miracle Mile Advisors LLC purchased a new stake in CRISPR Therapeutics during the 3rd quarter valued at $330,000. Twin Lakes Capital Management LLC bought a new position in shares of CRISPR Therapeutics in the 3rd quarter worth about $50,000. Finally, China Universal Asset Management Co. Ltd. grew its position in CRISPR Therapeutics by 1,744.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,583 shares of the company’s stock valued at $1,606,000 after purchasing an additional 23,250 shares during the last quarter. Institutional investors and hedge funds own 71.51% of the company’s stock.
CRISPR Therapeutics Stock Up 4.1 %
NASDAQ CRSP opened at $49.61 on Friday. The firm’s 50-day simple moving average is $49.65 and its two-hundred day simple moving average is $61.00. The company has a market cap of $3.88 billion, a PE ratio of -5.64 and a beta of 1.77. CRISPR Therapeutics AG has a 52 week low of $38.94 and a 52 week high of $86.95.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on CRSP shares. SVB Leerink lifted their price objective on shares of CRISPR Therapeutics from $75.00 to $76.00 and gave the company an “outperform” rating in a research report on Monday, November 7th. Citigroup cut their price objective on shares of CRISPR Therapeutics from $83.00 to $63.00 and set a “neutral” rating on the stock in a report on Wednesday, November 23rd. Credit Suisse Group dropped their target price on CRISPR Therapeutics from $90.00 to $78.00 in a research report on Wednesday, November 2nd. EF Hutton Acquisition Co. I initiated coverage on CRISPR Therapeutics in a research report on Thursday, January 5th. They issued a “buy” rating and a $75.00 price objective on the stock. Finally, Royal Bank of Canada decreased their target price on CRISPR Therapeutics from $79.00 to $70.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 2nd. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $98.22.
Insider Activity at CRISPR Therapeutics
In related news, CEO Samarth Kulkarni sold 25,000 shares of the business’s stock in a transaction on Wednesday, October 26th. The stock was sold at an average price of $54.81, for a total transaction of $1,370,250.00. Following the completion of the transaction, the chief executive officer now owns 290,279 shares in the company, valued at approximately $15,910,191.99. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 75,000 shares of company stock valued at $3,744,250. 5.30% of the stock is owned by company insiders.
CRISPR Therapeutics Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.